Boston Scientific lands cardiac patent win over Medtronic
September 18, 2012 by MassDevice staff
A Federal Circuit Court overturns a Medtronic win, sending the case back to a lower court to determine whether Medtronic's cardiac rhythm therapy devices infringe on Boston Scientific's exclusively licensed patents.
Medical device giants Medtronic (NYSE:MDT) and Boston Scientific (NYSE:BSX) will head back to court to hash out the details of a years-long patent battle over cardiac rhythm therapy device technology.
- Show full page
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Can Johnson & Johnson fire on all cylinders again?
- U.S. FDA to require proof of IEC 60601-1 3rd Edition in summer 2013
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
- Optimizing electronic medication administration records
- A bold new vision for Meditech
- Medtech storytelling in the era of comparative effectiveness
- Medical device sales: Wright Medical's pilot program on rep-less sales process worth watching
- Raising an early warning in the ICU: T3
- Staff shakeup underway at Russian medical device regulator
Navigation
NEWS
Can the FDA keep its user fee promises amid sequester?
The millions of dollars in fees that medical device companies pay for FDA review aren't exempt from...
Weight loss: EnteroMedics plans on Q1 PMA submission for Maestro device
EnteroMedics expects to file for pre-market approval from the FDA this quarter for its Maestro vagal...
Natus Medical's Q1 profits soar 1000%
Natus Medical beats Wall Street's earnings forecast with a 1,000-fold profit surge on record sales,...
Supreme Court to hear Medtronic's appeal of Boston Scientific's CRM patent win
The U.S. Supreme Court agrees to hear Medtronic's appeal of a patent infringement loss to rival...
Bayonne Medical Center tops 10 most expensive hospitals in America | MassDevice.com On-Call
The New York Times lists the 10 most expensive hospitals in the United States, based on CMS data
